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Abstract: Meningiomas are the most frequent non-glial primary brain tumors and represent about
30% of brain tumors. Usually, diagnosis and treatment planning are based on
neuroimaging using mainly magnetic resonance imaging (MRI) or rarely computed
tomography (CT). Most common treatment options are neurosurgical resection and
radiotherapy, e.g., radiosurgery or external fractionated radiotherapy. For follow-up
after treatment, structural imaging techniques such as MRI or CT are used. However,
these structural imaging modalities have limitations, particularly in terms of tumor
delineation as well as diagnosis of posttherapeutic reactive changes. Molecular
imaging techniques such as positron emission tomography (PET) can characterize
specific metabolic and cellular features which may provide clinically relevant
information beyond that obtained from structural MR or CT imaging alone. Currently,
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the use of PET in meningioma patients is steadily increasing. In the present article, we
provide recommendations for the use of PET imaging in the clinical management of
meningiomas based on evidence generated from studies being validated by histology
or clinical course.
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ABSTRACT 
Meningiomas are the most frequent non-glial primary brain tumors and represent 
about 30% of brain tumors. Usually, diagnosis and treatment planning are based on 
neuroimaging using mainly magnetic resonance imaging (MRI) or rarely computed 
tomography (CT). Most common treatment options are neurosurgical resection and 
radiotherapy, e.g., radiosurgery or external fractionated radiotherapy. For follow-up 
after treatment, structural imaging techniques such as MRI or CT are used. However, 
these structural imaging modalities have limitations, particularly in terms of tumor 
delineation as well as diagnosis of posttherapeutic reactive changes. Molecular 
imaging techniques such as positron emission tomography (PET) can characterize 
specific metabolic and cellular features which may provide clinically relevant 
information beyond that obtained from structural MR or CT imaging alone. Currently, 
the use of PET in meningioma patients is steadily increasing. In the present article, 
we provide recommendations for the use of PET imaging in the clinical management 
of meningiomas based on evidence generated from studies being validated by 
histology or clinical course. 
 
KEY WORDS 
MRI; positron emission tomography; ligand; somatostatin; menigiomas 
 
IMPORTANCE OF THE STUDY 
This paper seeks to summarize all so far published data on PET imaging in 
meningiomas which account for levels 1-3 evidence according to the Oxford Centre 
for evidence-based medicine in order to provide recommendations for the use as a 
guideline for clinicians. 
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INTRODUCTION 
Meningiomas are the most common primary brain tumors and represent 
approximately 30% of intracranial tumors. According to the classification of the World 
Health Organization (WHO), the majority of meningiomas are benign (WHO Grade I), 
exhibit slow growth and have a low recurrence rate (5-year overall recurrence rate 
following complete resection of about 5%) 1. In contrast, WHO grade II (atypical) and 
WHO grade III (malignant) meningiomas may show a more aggressive clinical 
behavior 2. Atypical and malignant meningiomas have 5-year overall recurrence rates 
of 40% and 80%, respectively 3. Molecular factors with strong prognostic information 
4,5 and potential value as predictive marker for targeted therapies have recently 
emerged 6-10. Most common treatment options are neurosurgical resection and 
various radiotherapy options such as radiosurgery or external fractionated 
radiotherapy 6. 
 
Contrast-enhanced structural imaging techniques such as magnetic resonance 
imaging (MRI) and computed tomography (CT, to delineate bony structures) are 
routinely used for defining the extent of the meningioma, treatment planning and 
monitoring as well as for follow-up after treatment, especially diagnosis of tumor 
recurrence. However, these structural imaging techniques have limitations in 
delineating meningiomas, especially at the skull base and in the case of bony 
involvement as well as in tumors with complex geometry 6. Furthermore, in the case 
of suspected residual or recurrent tumor, it can be challenging to distinguish viable 
tumor from scar tissue or posttherapeutic changes by CT or MRI alone, particularly 
after radiotherapy. 
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Molecular imaging modalities, which are not routinely used yet, may provide further 
diagnostic information. Positron emission tomography (PET) has meanwhile gained 
considerable importance for diagnostic purposes in general oncology. In 
neurooncology, particularly cerebral gliomas have been extensively studied using 
initially 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) and more recently amino acid PET 
tracers 11,12. In meningiomas, several tracers have been used including specific 
somatostatin receptor (SSTR) ligands such as 68Ga-DOTA-Tyr3-octreotide (68Ga-
DOTATOC), 68Ga-DOTA-D-Phe1-Tyr3-octreotate (68Ga-DOTATATE) or 68Ga-DOTA-
l-Nal3-octreotide (68Ga-DOTANOC). Currently, the number of PET examinations in 
meningioma patients is steadily increasing. The RANO Working Group/EANO 
recently pubished guidelines for the use of PET in gliomas 11; here we have prepared 
evidence-based recommendations for the use of PET imaging in the diagnosis and 
follow-up of patients with meningiomas to guide clinicians from all disciplines involved 
in the management of patients with these tumors.  
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SEARCH STRATEGY, SELECTION CRITERIA AND LEVELS OF VALIDATION  
A PubMed search of the published literature with the combination of the search terms 
“meningioma”, “PET”, “FDG”, “amino acid”, “somatostatin”, “DOTATOC”, 
“DOTATATE”, “DOTANOC”, “grading”, “delineation”, “radiotherapy”, and “extent” until 
September 2016 was performed.  Additionally, articles identified through searches of 
the authors’ own files were included in the search.  Results of the search were 
evaluated by the working group with respect to the level of evidence and the grade of 
validation of the PET studies examined. As described previously 11, any study that 
correlated the PET findings with histopathology was considered to represent the 
highest degree of validation. Next, correlation with MRI and with the patient’s clinical 
course was used for the second level of validation. Only papers constituting levels 1-
3 evidence according to the Oxford Centre for Evidence-based Medicine („The 
Oxford 2011 Levels of Evidence“) were included. 
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TRACERS FOR PET IMAGING IN MENINGIOMA PATIENTS  
Several tracers addressing different molecular structures or pathophysiological 
pathways in meningioma cells are available for PET imaging and will be summarized 
in the following paragraphs.  
  
Glucose PET  
18F-FDG represents the most widely used tracer in oncological PET imaging 13. With 
a half-life of the 18F isotope of 110 minutes, the tracer does not need in-house 
production, which facilitates supply. Therefore, 18F-FDG is available at all PET 
centers independently of the presence of a cyclotron. Due to an increased glycolysis 
in neoplastic tissue, uptake of 18F-FDG is generally higher than in non-neoplastic 
tissue 14,15. However, there are several limitations for the use of 18F-FDG in 
meningioma. Meningiomas are mostly slow-growing tumors and their glucose 
metabolism might be only moderately elevated 15-17 (Fig. 1). Furthermore, high 
physiological glucose uptake of the normal cerebral cortex leads to a low tumor-to-
background ratio and therefore limits the sensitivity for the detection of meningioma 
tissue and its delineation from adjacent brain parenchyma 18. Moreover, 18F-FDG 
uptake is not tumor-specific, but may be increased in inflammatory tissue 18.  
 
PET Ligands for Somatostatin Receptors 
Because of the overexpression of somatostatin receptors (SSTR) in meningiomas 19-
21, radiolabeled SSTR ligands can be used for the visualization of meningioma tissue. 
Somatostatin receptor subtype 2 has been found to be the most abundant isoform 
with almost 100% expression in meningiomas 19. The most commonly applied SSTR 
ligands for PET imaging are 68Ga-DOTATOC, 68Ga-DOTATATE and 68Ga-
DOTANOC. These tracers are also frequently used for imaging of neuroendocrine 
N-O-D-17-00255R2 
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tumors, which likewise express high levels of SSTR 22. 68Ga has a physical half-life of 
68 minutes and can be produced with a 68Ge/68Ga generator system, which enables 
in-house production without need of an on-site cyclotron. PET ligands to SSTR 
provide high sensitivity with excellent target-to-background contrast due to low 
uptake in bone and healthy brain tissue 23,24. However, the pituitary gland shows high 
physiological uptake which serves as a positive control but limits the exact 
delineation of meningioma extent in its close proximity 25. Up to now, a comparative 
study of 68Ga-DOTATOC, 68Ga-DOTATATE and 68Ga-DOTANOC in menigioma 
patients is not available. An animal study with nude mice bearing xenografts of a 
human meningioma cell line (CH-157MN) revealed similar uptake kinetics of the 
three tracers, but tumor uptake ratios were higher with 68Ga-DOTATATE, suggesting 
a higher diagnostic value of 68Ga-DOTATATE for detecting meningiomas 26. 
However, the uptake of all these tracers is relatively high compared to normal brain; 
thus, these differences are of less importance. Procedure guidelines for PET imaging 
with 68Ga-DOTA-conjugated peptides have been published previously 27. 
 
Amino acid PET Tracers 
Uptake of radiolabeled amino acids or their analogues such as [11C-methyl]-
methionine (11C-MET) and O-(2-[18F]-fluoroethyl)-L-tyrosine (18F-FET) is mediated by 
the L-amino acid transporter system, and increased uptake is already seen in slow-
growing tumors such as low-grade gliomas 28-30 and meningiomas 31,32.  
 
Amino acid PET tracers are widely used for glioma imaging as well as for the 
assessment of brain metastases after radiotherapy and has been integrated in many 
centers in clinical routine 11,12. Even though amino acid PET exhibits a better tumor-
to-background contrast than 18F-FDG PET 33, the availability of specific SSTR ligands 
N-O-D-17-00255R2 
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with even higher tumor-to-background contrast led to a limited use of amino acid PET 
in meningioma imaging 34,35. For the use of 11C-MET, an on-site cyclotron is needed 
due to the short half-life of 11C (20 minutes). In contrast, 18F-FET is (like 18F-FDG) 
labeled with 18F (half-life, 110 minutes) and can therefore be purchased and 
delivered independently of a local radiopharmaceutical setting. Interestingly, 18F-FET 
does not accumulate in the pituitary gland in comparison with 11C-MET and SSTR 
ligands, it may be superior in detecting intrasellar invasion of meningioma 36. For 
therapeutic procedures such as boron neutron capture therapy, boronated amino 
acid PET probes have been used in meningiomas 37,38. 
 
Other PET Tracers 
11C-Choline can be used as marker of increased phospholipid synthesis in tumor 
cells 39. Over the last years, it has been mostly used in prostate cancer and is 
currently being replaced by prostate specific membrane antigen (PSMA) ligands 39,40. 
As choline exhibits low uptake in the healthy brain tissue, the target-to-background 
contrast is good as well, but the experience in meningioma patients is limited to case 
reports so far, and only one small study on 7 patients compared the value of 11C-
choline with 18F-FDG PET in meningiomas indicating a higher target-to-background 
contrast for 11C-choline than for 18F-FDG 41.  
 
11C-Acetate is another possible PET tracer which has been used in extracranial 
tumors which are difficult to detect by 18F-FDG PET, such as renal carcinoma, 
prostate cancer or hepatocellular carcinoma 42-44. 11C-Acetate uptake in tumor cells 
depends on the activation of anabolic pathways of fatty acids and sterol synthesis 
18,45. The experience with this tracer for meningioma imaging is also very limited. So 
far, only one study on 22 patients has been published, stating that the tracer is 
N-O-D-17-00255R2 
 
 10 
superior to 18F-FDG for the detection of meningioma and delineation of tumor extent 
for radiosurgery planning and the evaluation of treatment response 18. 
 
18F-Fluoride, which is used in imaging of bone metastasis of neoplastic tissue, might 
facilitate detection of bone invasion of meningiomas. There are two studies reporting 
superior detection of bone involvement with 18F-Fluoride compared to CT and MRI, 
which might assist in planning of surgery 46,47.  
 
Aside from PET imaging with specific purpose of meningioma imaging, meningiomas 
might be detected incidentally on PET scans using 11C-PIB (Pittsburgh compound B) 
in patients with Alzheimer’s disease 48, 68Ga-labeled prostate-specific membrane 
antigen (PSMA) ligand PET 49 or dopamine transporter imaging in patients with 
Parkinson syndromes 50. 
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CLINICAL APPLICATIONS FOR PET IMAGING  
Diagnosis / Differential Diagnosis  
Mostly, meningiomas are well-defined, extra-axial masses, which may displace the 
adjacent brain. Furthermore, the cerebrospinal fluid (CSF) cleft sign can be present, 
representing a thin rim of CSF between tumor and brain parenchyma. Sometimes, 
however, meningiomas may become very large before causing clinical symptoms, 
and, furthermore, the distinction between an intraaxial and extraaxial origin may be 
difficult 51. Several other disease processes have a propensity for primary 
involvement of the dura mater or subdural space giving a meningioma-like 
appearance, including lymphomas, brain metastases, other benign tumors (e.g., 
schwannomas), inflammatory lesions (e.g., neurosarcoidosis, Wegener’s 
granulomatosis), and infections of the central nervous system (e.g., tuberculosis) 52.  
 
Although PET plays no major role in the primary diagnosis of meningiomas, SSTR 
imaging may be helpful in terms of gross and clinical target volume definition (GTV, 
CTV). A study comparing contrast-enhanced MRI and 68Ga-DOTATOC PET/CT prior 
to radiotherapy reported that all meningiomas (n=190) were detected by PET/CT. In 
contrast, only 171 meningiomas were detected by contrast-enhanced MRI (90%) 
indicating an improved sensitivity for 68Ga-DOTATOC PET in meningioma detection 
when compared to contrast-enhanced MRI 24. Particularly, tumors adjacent to the falx 
cerebri, located at the skull base, infiltrating bony structures or being obscured by 
imaging artefacts or calcification were difficult to detect by standard MRI alone (Fig. 
2). The authors concluded that 68Ga-DOTATOC PET/CT may provide additional 
information in patients with uncertain or equivocal results on MRI or could help to 
confirm a diagnosis of meningioma based on MRI. Moreover, 68Ga-DOTATATE 
PET/CT helps to discriminate optic nerve sheath meningiomas in the differential 
N-O-D-17-00255R2 
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diagnosis of other lesions being associated with the optic nerve 53 (Fig. 3). In a 
comparative study between MRI and 68Ga-DOTATATE PET/CT, additional 
meningiomas were detected by PET, some of them even in retrospect not being 
visible yet in MRI 23. 
 
However, expression of somatostatin receptors may also be observed in 
esthesioneuroblastomas, leukocytes accumulating in chronic inflammatory tissue, 
pituitary tumors, gliomas, fibrous dysplasia of the bone, Paget’s disease, and brain 
metastases originating from various extracranial tumors, e.g., breast cancer 24,27. 
Such lesions, however, usually present with a lower uptake and with a distinct 
morphology and location that differ from meningiomas.  
 
 PET ligands for somatostatin receptors may add valuable diagnostic 
information to standard MRI in newly diagnosed brain lesions suspicious for 
meningiomas, especially concerning differential diagnosis and sensitivity to 
detect lesions (evidence level 2). 
 
 
Tumor Grading  
The uptake of 18F-FDG correlates significantly with the WHO grade in meningiomas 
14,15, but as a major limitation its uptake is not tumor-specific and may be increased in 
inflammatory tissue 18. 11C-Choline may overcome this limitation and may be helpful 
for meningioma grading as well 41, but the present results are preliminary. Regarding 
PET ligands to SSTR, 68Ga-DOTATATE binding correlates with tumor growth rate in 
WHO grade I and II meningiomas, but is abolished in anaplastic (WHO grade III) 
meningiomas 35. Data on the amino acid tracer 11C-MET suggest a correlation with 
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proliferative acivity in meningiomas 54, but are controversial for noninvasive 
meningioma grading 34,55. Furthermore, its use is strictly limited to centers with an on-
site cyclotron unit. Preliminary findings revealed that static and dynamic 18F-FET 
parameters may provide additional information for noninvasive grading of 
meningiomas 32. The tracer 11C-Acetate seems not to be helpful for meningioma 
grading 18. 
 
 Up to now, only preliminary evidence for a potential benefit of PET for 
noninvasive meningioma grading is present (evidence level 3). 
 
 
Delineation of Tumor Extent 
A prerequisite for an improved delineation of tumor extent is a high tumor-to-
background ratio derived from the administered PET tracer, preferably higher than 
the contrast that can be achieved by contrast-enhanced MRI (Fig. 4). Furthermore, 
regarding meningioma delineation, several different tissues are to be respected as 
background (e.g., brain, bone, blood, fibrotic tissue, and inflammatory lesions). Due 
to usually high levels of glucose in healthy brain parenchyma causing a poor tumor-
to-background contrast, the tracer 18F-FDG is not suitable for precise tumor 
delineation 17. On the other hand, PET ligands to SSTR and radiolabeled amino acids 
generally elicit high tumor-to-background ratios. In a comparative study using neuro-
navigated tissue sampling with histological confirmation, in various tumor locations 
68Ga-DOTATATE revealed a more precise delineation of tumor extent than contrast-
enhanced MRI 23. Furthermore, in meningiomas with osseus infiltration as well as in 
regions such as the skull base, orbita, and cavernous sinus, PET using 68Ga-
DOTATATE and 68Ga-DOTATOC was also reported to provide a better tumor 
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delineation than MRI 25,56,57. In the latter studies, however, histological confirmation of 
imaging findings was not performed. Similarly, studies using 11C-MET or 2-[18F]-
fluoro-L-tyrosine reported an improved tumor delineation compared to MRI, but 
again, without histological confirmation 31,58,59. In one retrospective study with 
histological evaluation, 18F-Fluoride improved preoperative detection of bone 
infiltration 46. 
 
 Different PET tracers might facilitate tumor delineation in meningiomas, 
especially in regions with low MR and CT contrast such as the skull base, 
orbita, parafalcine area with involvement of the sagittal sinus, cavernous 
sinus, and any transosseus growth; best evidence exists currently for 68Ga-
DOTATATE (evidence level 2). 
 
 
Value for Treatment Planning 
Resection  
Whenever treatment is considered in newly diagnosed meningiomas, surgical 
resection is the mainstay of therapy in the majority of locations. The surgical goal 
should be total excision of the lesion including the involved dura 6,60. In order to 
achieve this goal, the exact delineation of the tumor has to be fully visualized prior to 
surgery since bony involvement and extended dural infiltration might not be 
recognizable, even with the use of an operating microscope. This is especially the 
case for regions with low MR and CT contrast such as the skull base, orbita, 
parafalcine area with involvement of the sagittal sinus, cavernous sinus, and any 
transosseus growth. Histology-controlled and imaging-guided resection studies using 
both 68Ga-DOTATATE PET and MRI showed that 68Ga-DOTATATE PET delineates 
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better the extent of meningiomas than contrast-enhanced MRI alone 23,61. Equally 
important, 68Ga-DOTATATE PET helps to discriminate between recurrent tumor and 
scar tissue after previous surgery or radiotherapy with higher sensitivity and equal 
specificity than MRI 23. This is of additional value to tailor the resection especially in 
recurrent, pretreated tumors. Thus, 68Ga-DOTATATE PET provides additional 
valuable information regarding extent and localization of meningioma tissue, 
especially when this information is being integrated into neuronavigation systems 62. 
 
 68Ga-DOTATATE PET improves the delineation of tumor extent in 
meningiomas with potential benefits for tumor resection (evidence level 2). 
 
 
Radiation Treatment Planning 
Target volume delineation plays a crucial role in the planning of high precision 
radiation therapy such as radiosurgery and stereotactic fractionated radiotherapy. In 
meningiomas, the GTV and the CTV is delineated based on image fusion of contrast-
enhanced CT and MRI. Usually, contrast-enhanced MRI visualizes very well the 
GTV. However, in a considerable number of cases, especially in tumors located at 
the skull base (meningiomas of the suprasellar region and the sphenoid wings 
comprise approximately 30% of cases), it is difficult to differentiate between normal 
dura tissue and tumor tissue, because normal dura as well as bone show a high 
contrast enhancement. Moreover, in tumors infiltrating the bone it is difficult to define 
the infiltration depth with high precision, despite using the bone window on CT 
images. In these cases, PET imaging may add helpful information. Furthermore, in 
postoperative MRI with inconclusive findings (e.g., reactive changes), PET may aid in 
the identification of active tumor remnants in the planning of adjuvant radiotherapy 
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after subtotal or partial tumor resection. For RT planning, it is necessary to fuse the 
PET with MRI/CT due to the lower spatial resolution of PET alone. 
 
11C-MET PET can be integrated in radiation treatment planning 63 and significantly 
influence GTV delineation in meningiomas. Astner and colleagues demonstrated that 
in 32 patients with benign skull base meningiomas treated with stereotactic 
fractionated radiotherapy the addition of 11C-MET PET changed the GTV in all but 
three patients 31. In that study, 11C-MET PET detected tumor areas with a mean 
volume of 1.6 ml, which were not visualized on CT or MRI, leading to an enlargement 
of GTV of approximately 9%. At the same time, areas without tumor infiltration could 
be excluded from the GTV and critical structures like optic nerves, the chiasm or the 
pituitary gland could be spared more effectively 31. Furthermore, regarding the GTV 
definition, the addition of 11C-MET PET to CT and MRI helps to significantly lower the 
interobserver variability in comparison to MRI and CT alone 59. Subsequently, other 
groups have confirmed these findings using other radiolabeled amino acids 58. 
 
Milker-Zabel et al. demonstrated an optimized target volume delineation for 
stereotactic fractionated radiation therapy in grade I-III meningiomas using 68Ga-
DOTATOC PET co-registered to CT and MRI 56. In all patients, 68Ga-DOTATOC PET 
delivered additional information concerning meningioma extent for fractionated 
stereotactic radiotherapy target definition. These results are supported by data 
reported subsequently by other groups 57,64,65 (Fig. 5, 6). 
 
 Amino acid PET and 68Ga-DOTATOC PET add valuable diagnostic 
information for meningioma delineation, particularly helpful for radiotherapy 
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planning by improving both GTV definition and dose sparing of organs at risk 
(evidence level 2).  
 
 
Follow-up: Treatment Response, Progression  
In a prospective study with 19 meningioma patients, serial 11C-MET PET scans were 
used to evaluate the effect of stereotactic high-energy proton beam treatment (24 Gy 
in four consecutive daily 6-Gy fractions) 66. The authors observed no significant 
reduction of tumor size but an average tumor/brain ratio reduction of 19% in the total 
patient group, suggesting that 11C-MET PET may enable an earlier evaluation of 
treatment effects than CT or MRI. The long-term evaluation over 10 years of the 
same patient cohort revealed that in the majority of patients MET uptake ratios 
showed a further decrease, whereas the tumor size was predominantly unchanged 
throughout the follow-up 67. As 68Ga-DOTATOC PET is superior in both 
discriminating meningioma tissue from scars related to pretreatment and detecting 
meningiomas not (yet) seen in MRI, it is useful in cases of unclear differential 
diagnosis between tumor progression and posttherapeutic reactive changes 23,24,52. 
For the discrimination of scar tissue from vital tumor, Rachinger and colleagues 
demonstrated that standard MRI has a lower diagnostic performance than 68Ga-
DOTATATE PET: sensitivity, 79% vs. 90%; specificity, 65% vs. 74%; and positive 
predictive value, 84% vs. 89% 23. In line with this, a more recent 68Ga-DOTATATE 
PET study with focus on transosseous growing meningiomas showed an even better 
diagnostic performance for pretreated lesions than standard MRI (sensitivity, 97% vs. 
54%; specificity, 100% vs. 83%; positive predictive value, 100% vs. 95%; and 
negative predictive value, 86% vs. 23%) 61.  
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 Up to now, only preliminary evidence for a potential benefit of amino acid PET 
for treatment monitoring of radiotherapy is present (evidence level 3). 
 
 68Ga-DOTATOC PET can be useful in cases of unclear differential diagnosis 
between tumor progression and posttherapeutic reactive changes (evidence 
level 2). 
 
 
CURRENT LIMITATIONS  
PET data in relation to the clinical management of meningioma patients have 
predominantly been reported for small, retrospectively assembled patient series, and 
data were usually obtained in monocentric studies. Recent encouraging findings in 
this field should therefore be validated in larger clinical prospective multicenter 
cohorts and trials. Moreover, further studies evaluating the correlation between PET 
imaging findings and histology are necessary and essential to define more accurately 
the impact of PET in this group of patients. Importantly, it has still to be demonstrated 
that a better tumor delineation allows better long term tumor control. Another 
methodical concern of using PET for planning radiotherapy of meningioma is the 
definition of threshold values defining the radiation volumes (e.g., GTV). Because 
meningiomas may have microscopic tumor growth and PET has a limited spatial 
resolution, empirical margins have to be added. 
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OUTLOOK PERSPECTIVE  
 
Radiopeptide therapy  
 
By exchanging the radionuclide, the same tracer can be use either for diagnostics or 
for therapy (“theranostics”). The principle of peptide receptor radionuclide therapy 
(PRRT) is well established in the management of neuroendocrine tumors 68, and 
more recently, has been introduced to meningioma treatment. An exchange of the 
short-lived positron emitter Gallium-68 used for PET with the longer-lived β-emitters 
Lutetium-177 or Yttrium-90 allows for receptor-targeted therapy. Due to the wide 
application in neuroendocrine tumors, the safety profile of SSTR-based PRRT is 
known and therapy is generally well tolerated.  
 
Eight studies and one single-case study on PRRT treatment in meningioma have 
been published, reporting on 90Y-DOTATOC, 177Lu-DOTATATE and 111In-
pentetreotide therapy in 124 patients 69-77. However, due to retro- and prospective 
study designs, mixed patient populations, differences in administered doses and 
varying response assessments as well as follow-up interval, pooling of the present 
data is complex. Nevertheless, the high rate of reported disease stabilization and the 
possibility of a patient- or lesion-tailored therapy make PRRT a promising tool; 
however, future studies should include an adequate sample size with clear inclusion 
criteria, preferably include a comparator to PRRT and rigorous response assessment 
to determine the role of PRRT in meningioma management. In the future perspective, 
PRRT may be further optimized by a change to α-emitters and local application of the 
substance to increase the locally administered dose 78,79. 
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CONCLUSION 
Compared to standard MRI, particularly PET ligands to SSTR (receptor subtype 2) 
add valuable additional diagnostic information. Based on the current levels of 
evidence, the most relevant indications for this group of tracers are differential 
diagnosis of newly diagnosed brain lesions suspicious for meningiomas, the 
delineation of meningioma extent in regions with low MR and CT contrast (e.g., 
osseus infiltration) and complex anatomy (e.g., skull base) for resection or 
radiotherapy planning, and the differentiation of tumor progression from 
posttherapeutic reactive changes such as scar tissue or radiation necrosis. The 
evidence in this field justifies therefore a further validation in larger prospective 
multicenter clinical cohorts and trials for which standardized technical guidelines for 
imaging and readout procedures will now be developed. 
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FIGURE LEGENDS 
Figure 1: 43-year-old male patient with a newly diagnosed left temporal meningioma 
(WHO grade I), preoperatively examined by multimodal imaging. Both contrast-
enhanced MRI and 18F-FET PET allow a precise tumor delineation. Conversely, 18F-
FDG PET shows decreased metabolic activity, indicating its limitation for the 
evaluation of meningioma extent. 
  
Figure 2: Postoperative contrast-enhanced MRI and 68Ga-DOTATATE PET/CT of a 
32-year-old patient after resection of a WHO grade I meningioma shows residual 
tumor located at the left internal carotid artery and at tumor at the tip of the left orbit 
(A, D). Surprisingly, two additional meningiomas were also visible on the 68Ga-
DOTATATE PET/CT (E, F), without corresponding contrast enhancement on MRI (B, 
C).       
  
Figure 3: 43-year-old female patient with a history of a meningioma of the left optical 
sheath treated with surgery and radiotherapy eight years ago. At follow-up, 68Ga-
DOTATATE-PET/CT reveals multiple meningioma lesions including meningioma 
recurrence at the optical sheath (arrows). 
  
Figure 4: Amino acid PET with 18F-FET and contrast-enhanced MR images of a 68-
year-old female meningioma patient (WHO grade I) with suspected recurrence 9 
years after tumor resection at initial diagnosis. 18F-FET PET identifies three 
hypermetabolic lesions, consistent with meningioma recurrence. In contrast, MRI 
shows prominent contrast enhancement in only two of three lesions. In that lesion 
(arrow, bottom), contrast enhancement is subtle and not well defined. 18F-FET PET 
allows an improved delineation of this lesion (arrow, top). 
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Figure 5: 42-year-old patient with exophthalmus and a history of a left sphenoid wing 
meningioma. Preoperative MRI shows tumor recurrence (top). Postoperative MRI 
(bottom left) shows an incomplete resection of the tumor, necessitating adjuvant 
radiotherapy. For radiotherapy planning, 68Ga-DOTATATE PET/CT reveals an 
additional tumor located at the tip of the right sphenoid wing (arrow, bottom right). 
 
Figure 6: Patient with a WHO grade I meningioma (arrows). In contrast to structural 
MRI, particularly 68Ga-DOTATOC PET delineates meningioma extent more precisely. 
For radiotherapy planning, the contralateral unaffected side can be spared.
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ABSTRACT 
Meningiomas are the most frequent non-glial primary brain tumors and represent 
about 30% of brain tumors. Usually, diagnosis and treatment planning are based on 
neuroimaging using mainly magnetic resonance imaging (MRI) or rarely computed 
tomography (CT). Most common treatment options are neurosurgical resection and 
radiotherapy, e.g., radiosurgery or external fractionated radiotherapy. For follow-up 
after treatment, structural imaging techniques such as MRI or CT are used. However, 
these structural imaging modalities have limitations, particularly in terms of tumor 
delineation as well as diagnosis of posttherapeutic reactive changes. Molecular 
imaging techniques such as positron emission tomography (PET) can characterize 
specific metabolic and cellular features which may provide clinically relevant 
information beyond that obtained from structural MR or CT imaging alone. Currently, 
the use of PET in meningioma patients is steadily increasing. In the present article, 
we provide recommendations for the use of PET imaging in the clinical management 
of meningiomas based on evidence generated from studies being validated by 
histology or clinical course. 
 
KEY WORDS 
MRI; positron emission tomography; ligand; somatostatin; menigiomas 
 
IMPORTANCE OF THE STUDY 
This paper seeks to summarize all so far published data on PET imaging in 
meningiomas which account for levels 1-3 evidence according to the Oxford Centre 
for evidence-based medicine in order to provide recommendations for the use as a 
guideline for clinicians. 
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INTRODUCTION 
Meningiomas are the most common primary brain tumors and represent 
approximately 30% of intracranial tumors. According to the classification of the World 
Health Organization (WHO), the majority of meningiomas are benign (WHO Grade I), 
exhibit slow growth and have a low recurrence rate (5-year overall recurrence rate 
following complete resection of about 5%) 1. In contrast, WHO grade II (atypical) and 
WHO grade III (malignant) meningiomas may show a more aggressive clinical 
behavior 2. Atypical and malignant meningiomas have 5-year overall recurrence rates 
of 40% and 80%, respectively 3. Molecular factors with strong prognostic information 
4,5 and potential value as predictive marker for targeted therapies have recently 
emerged 6-10. Most common treatment options are neurosurgical resection and 
various radiotherapy options such as radiosurgery or external fractionated 
radiotherapy 6. 
 
Contrast-enhanced structural imaging techniques such as magnetic resonance 
imaging (MRI) and computed tomography (CT, to delineate bony structures) are 
routinely used for defining the extent of the meningioma, treatment planning and 
monitoring as well as for follow-up after treatment, especially diagnosis of tumor 
recurrence. However, these structural imaging techniques have limitations in 
delineating meningiomas, especially at the skull base and in the case of bony 
involvement as well as in tumors with complex geometry 6. Furthermore, in the case 
of suspected residual or recurrent tumor, it can be challenging to distinguish viable 
tumor from scar tissue or posttherapeutic changes by CT or MRI alone, particularly 
after radiotherapy. 
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Molecular imaging modalities, which are not routinely used yet, may provide further 
diagnostic information. Positron emission tomography (PET) has meanwhile gained 
considerable importance for diagnostic purposes in general oncology. In 
neurooncology, particularly cerebral gliomas have been extensively studied using 
initially 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) and more recently amino acid PET 
tracers 11,12. In meningiomas, several tracers have been used including specific 
somatostatin receptor (SSTR) ligands such as 68Ga-DOTA-Tyr3-octreotide (68Ga-
DOTATOC), 68Ga-DOTA-D-Phe1-Tyr3-octreotate (68Ga-DOTATATE) or 68Ga-DOTA-
l-Nal3-octreotide (68Ga-DOTANOC). Currently, the number of PET examinations in 
meningioma patients is steadily increasing. The RANO Working Group/EANO 
recently pubished guidelines for the use of PET in gliomas 11; here we have prepared 
evidence-based recommendations for the use of PET imaging in the diagnosis and 
follow-up of patients with meningiomas to guide clinicians from all disciplines involved 
in the management of patients with these tumors.  
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SEARCH STRATEGY, SELECTION CRITERIA AND LEVELS OF VALIDATION  
A PubMed search of the published literature with the combination of the search terms 
“meningioma”, “PET”, “FDG”, “amino acid”, “somatostatin”, “DOTATOC”, 
“DOTATATE”, “DOTANOC”, “grading”, “delineation”, “radiotherapy”, and “extent” until 
September 2016 was performed.  Additionally, articles identified through searches of 
the authors’ own files were included in the search.  Results of the search were 
evaluated by the working group with respect to the level of evidence and the grade of 
validation of the PET studies examined. As described previously 11, any study that 
correlated the PET findings with histopathology was considered to represent the 
highest degree of validation. Next, correlation with MRI and with the patient’s clinical 
course was used for the second level of validation. Only papers constituting levels 1-
3 evidence according to the Oxford Centre for Evidence-based Medicine („The 
Oxford 2011 Levels of Evidence“) were included. 
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TRACERS FOR PET IMAGING IN MENINGIOMA PATIENTS  
Several tracers addressing different molecular structures or pathophysiological 
pathways in meningioma cells are available for PET imaging and will be summarized 
in the following paragraphs.  
  
Glucose PET  
18F-FDG represents the most widely used tracer in oncological PET imaging 13. With 
a half-life of the 18F isotope of 110 minutes, the tracer does not need in-house 
production, which facilitates supply. Therefore, 18F-FDG is available at all PET 
centers independently of the presence of a cyclotron. Due to an increased glycolysis 
in neoplastic tissue, uptake of 18F-FDG is generally higher than in non-neoplastic 
tissue 14,15. However, there are several limitations for the use of 18F-FDG in 
meningioma. Meningiomas are mostly slow-growing tumors and their glucose 
metabolism might be only moderately elevated 15-17 (Fig. 1). Furthermore, high 
physiological glucose uptake of the normal cerebral cortex leads to a low tumor-to-
background ratio and therefore limits the sensitivity for the detection of meningioma 
tissue and its delineation from adjacent brain parenchyma 18. Moreover, 18F-FDG 
uptake is not tumor-specific, but may be increased in inflammatory tissue 18.  
 
PET Ligands for Somatostatin Receptors 
Because of the overexpression of somatostatin receptors (SSTR) in meningiomas 19-
21, radiolabeled SSTR ligands can be used for the visualization of meningioma tissue. 
Somatostatin receptor subtype 2 has been found to be the most abundant isoform 
with almost 100% expression in meningiomas 19. The most commonly applied SSTR 
ligands for PET imaging are 68Ga-DOTATOC, 68Ga-DOTATATE and 68Ga-
DOTANOC. These tracers are also frequently used for imaging of neuroendocrine 
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tumors, which likewise express high levels of SSTR 22. 68Ga has a physical half-life of 
68 minutes and can be produced with a 68Ge/68Ga generator system, which enables 
in-house production without need of an on-site cyclotron. PET ligands to SSTR 
provide high sensitivity with excellent target-to-background contrast due to low 
uptake in bone and healthy brain tissue 23,24. However, the pituitary gland shows high 
physiological uptake which serves as a positive control but limits the exact 
delineation of meningioma extent in its close proximity 25. Up to now, a comparative 
study of 68Ga-DOTATOC, 68Ga-DOTATATE and 68Ga-DOTANOC in menigioma 
patients is not available. An animal study with nude mice bearing xenografts of a 
human meningioma cell line (CH-157MN) revealed similar uptake kinetics of the 
three tracers, but tumor uptake ratios were higher with 68Ga-DOTATATE, suggesting 
a higher diagnostic value of 68Ga-DOTATATE for detecting meningiomas 26. 
However, the uptake of all these tracers is relatively high compared to normal brain; 
thus, these differences are of less importance. Procedure guidelines for PET imaging 
with 68Ga-DOTA-conjugated peptides have been published previously 27. 
 
Amino acid PET Tracers 
Uptake of radiolabeled amino acids or their analogues such as [11C-methyl]-
methionine (11C-MET) and O-(2-[18F]-fluoroethyl)-L-tyrosine (18F-FET) is mediated by 
the L-amino acid transporter system, and increased uptake is already seen in slow-
growing tumors such as low-grade gliomas 28-30 and meningiomas 31,32.  
 
Amino acid PET tracers are widely used for glioma imaging as well as for the 
assessment of brain metastases after radiotherapy and has been integrated in many 
centers in clinical routine 11,12. Even though amino acid PET exhibits a better tumor-
to-background contrast than 18F-FDG PET 33, the availability of specific SSTR ligands 
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with even higher tumor-to-background contrast led to a limited use of amino acid PET 
in meningioma imaging 34,35. For the use of 11C-MET, an on-site cyclotron is needed 
due to the short half-life of 11C (20 minutes). In contrast, 18F-FET is (like 18F-FDG) 
labeled with 18F (half-life, 110 minutes) and can therefore be purchased and 
delivered independently of a local radiopharmaceutical setting. Interestingly, 18F-FET 
does not accumulate in the pituitary gland in comparison with 11C-MET and SSTR 
ligands, it may be superior in detecting intrasellar invasion of meningioma 36. For 
therapeutic procedures such as boron neutron capture therapy, boronated amino 
acid PET probes have been used in meningiomas 37,38. 
 
Other PET Tracers 
11C-Choline can be used as marker of increased phospholipid synthesis in tumor 
cells 39. Over the last years, it has been mostly used in prostate cancer and is 
currently being replaced by prostate specific membrane antigen (PSMA) ligands 39,40. 
As choline exhibits low uptake in the healthy brain tissue, the target-to-background 
contrast is good as well, but the experience in meningioma patients is limited to case 
reports so far, and only one small study on 7 patients compared the value of 11C-
choline with 18F-FDG PET in meningiomas indicating a higher target-to-background 
contrast for 11C-choline than for 18F-FDG 41.  
 
11C-Acetate is another possible PET tracer which has been used in extracranial 
tumors which are difficult to detect by 18F-FDG PET, such as renal carcinoma, 
prostate cancer or hepatocellular carcinoma 42-44. 11C-Acetate uptake in tumor cells 
depends on the activation of anabolic pathways of fatty acids and sterol synthesis 
18,45. The experience with this tracer for meningioma imaging is also very limited. So 
far, only one study on 22 patients has been published, stating that the tracer is 
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superior to 18F-FDG for the detection of meningioma and delineation of tumor extent 
for radiosurgery planning and the evaluation of treatment response 18. 
 
18F-Fluoride, which is used in imaging of bone metastasis of neoplastic tissue, might 
facilitate detection of bone invasion of meningiomas. There are two studies reporting 
superior detection of bone involvement with 18F-Fluoride compared to CT and MRI, 
which might assist in planning of surgery 46,47.  
 
Aside from PET imaging with specific purpose of meningioma imaging, meningiomas 
might be detected incidentally on PET scans using 11C-PIB (Pittsburgh compound B) 
in patients with Alzheimer’s disease 48, 68Ga-labeled prostate-specific membrane 
antigen (PSMA) ligand PET 49 or dopamine transporter imaging in patients with 
Parkinson syndromes 50. 
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CLINICAL APPLICATIONS FOR PET IMAGING  
Diagnosis / Differential Diagnosis  
Mostly, meningiomas are well-defined, extra-axial masses, which may displace the 
adjacent brain. Furthermore, the cerebrospinal fluid (CSF) cleft sign can be present, 
representing a thin rim of CSF between tumor and brain parenchyma. Sometimes, 
however, meningiomas may become very large before causing clinical symptoms, 
and, furthermore, the distinction between an intraaxial and extraaxial origin may be 
difficult 51. Several other disease processes have a propensity for primary 
involvement of the dura mater or subdural space giving a meningioma-like 
appearance, including lymphomas, brain metastases, other benign tumors (e.g., 
schwannomas), inflammatory lesions (e.g., neurosarcoidosis, Wegener’s 
granulomatosis), and infections of the central nervous system (e.g., tuberculosis) 52.  
 
Although PET plays no major role in the primary diagnosis of meningiomas, SSTR 
imaging may be helpful in terms of gross and clinical target volume definition (GTV, 
CTV). A study comparing contrast-enhanced MRI and 68Ga-DOTATOC PET/CT prior 
to radiotherapy reported that all meningiomas (n=190) were detected by PET/CT. In 
contrast, only 171 meningiomas were detected by contrast-enhanced MRI (90%) 
indicating an improved sensitivity for 68Ga-DOTATOC PET in meningioma detection 
when compared to contrast-enhanced MRI 24. Particularly, tumors adjacent to the falx 
cerebri, located at the skull base, infiltrating bony structures or being obscured by 
imaging artefacts or calcification were difficult to detect by standard MRI alone (Fig. 
2). The authors concluded that 68Ga-DOTATOC PET/CT may provide additional 
information in patients with uncertain or equivocal results on MRI or could help to 
confirm a diagnosis of meningioma based on MRI. Moreover, 68Ga-DOTATATE 
PET/CT helps to discriminate optic nerve sheath meningiomas in the differential 
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diagnosis of other lesions being associated with the optic nerve 53 (Fig. 3). In a 
comparative study between MRI and 68Ga-DOTATATE PET/CT, additional 
meningiomas were detected by PET, some of them even in retrospect not being 
visible yet in MRI 23. 
 
However, expression of somatostatin receptors may also be observed in 
esthesioneuroblastomas, leukocytes accumulating in chronic inflammatory tissue, 
pituitary tumors, gliomas, fibrous dysplasia of the bone, Paget’s disease, and brain 
metastases originating from various extracranial tumors, e.g., breast cancer 24,27. 
Such lesions, however, usually present with a lower uptake and with a distinct 
morphology and location that differ from meningiomas.  
 
 PET ligands for somatostatin receptors may add valuable diagnostic 
information to standard MRI in newly diagnosed brain lesions suspicious for 
meningiomas, especially concerning differential diagnosis and sensitivity to 
detect lesions (evidence level 2). 
 
 
Tumor Grading  
The uptake of 18F-FDG correlates significantly with the WHO grade in meningiomas 
14,15, but as a major limitation its uptake is not tumor-specific and may be increased in 
inflammatory tissue 18. 11C-Choline may overcome this limitation and may be helpful 
for meningioma grading as well 41, but the present results are preliminary. Regarding 
PET ligands to SSTR, 68Ga-DOTATATE binding correlates with tumor growth rate in 
WHO grade I and II meningiomas, but is abolished in anaplastic (WHO grade III) 
meningiomas 35. Data on the amino acid tracer 11C-MET suggest a correlation with 
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proliferative acivity in meningiomas 54, but are controversial for noninvasive 
meningioma grading 34,55. Furthermore, its use is strictly limited to centers with an on-
site cyclotron unit. Preliminary findings revealed that static and dynamic 18F-FET 
parameters may provide additional information for noninvasive grading of 
meningiomas 32. The tracer 11C-Acetate seems not to be helpful for meningioma 
grading 18. 
 
 Up to now, only preliminary evidence for a potential benefit of PET for 
noninvasive meningioma grading is present (evidence level 3). 
 
 
Delineation of Tumor Extent 
A prerequisite for an improved delineation of tumor extent is a high tumor-to-
background ratio derived from the administered PET tracer, preferably higher than 
the contrast that can be achieved by contrast-enhanced MRI (Fig. 4). Furthermore, 
regarding meningioma delineation, several different tissues are to be respected as 
background (e.g., brain, bone, blood, fibrotic tissue, and inflammatory lesions). Due 
to usually high levels of glucose in healthy brain parenchyma causing a poor tumor-
to-background contrast, the tracer 18F-FDG is not suitable for precise tumor 
delineation 17. On the other hand, PET ligands to SSTR and radiolabeled amino acids 
generally elicit high tumor-to-background ratios. In a comparative study using neuro-
navigated tissue sampling with histological confirmation, in various tumor locations 
68Ga-DOTATATE revealed a more precise delineation of tumor extent than contrast-
enhanced MRI 23. Furthermore, in meningiomas with osseus infiltration as well as in 
regions such as the skull base, orbita, and cavernous sinus, PET using 68Ga-
DOTATATE and 68Ga-DOTATOC was also reported to provide a better tumor 
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delineation than MRI 25,56,57. In the latter studies, however, histological confirmation of 
imaging findings was not performed. Similarly, studies using 11C-MET or 2-[18F]-
fluoro-L-tyrosine reported an improved tumor delineation compared to MRI, but 
again, without histological confirmation 31,58,59. In one retrospective study with 
histological evaluation, 18F-Fluoride improved preoperative detection of bone 
infiltration 46. 
 
 Different PET tracers might facilitate tumor delineation in meningiomas, 
especially in regions with low MR and CT contrast such as the skull base, 
orbita, parafalcine area with involvement of the sagittal sinus, cavernous 
sinus, and any transosseus growth; best evidence exists currently for 68Ga-
DOTATATE (evidence level 2). 
 
 
Value for Treatment Planning 
Resection  
Whenever treatment is considered in newly diagnosed meningiomas, surgical 
resection is the mainstay of therapy in the majority of locations. The surgical goal 
should be total excision of the lesion including the involved dura 6,60. In order to 
achieve this goal, the exact delineation of the tumor has to be fully visualized prior to 
surgery since bony involvement and extended dural infiltration might not be 
recognizable, even with the use of an operating microscope. This is especially the 
case for regions with low MR and CT contrast such as the skull base, orbita, 
parafalcine area with involvement of the sagittal sinus, cavernous sinus, and any 
transosseus growth. Histology-controlled and imaging-guided resection studies using 
both 68Ga-DOTATATE PET and MRI showed that 68Ga-DOTATATE PET delineates 
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better the extent of meningiomas than contrast-enhanced MRI alone 23,61. Equally 
important, 68Ga-DOTATATE PET helps to discriminate between recurrent tumor and 
scar tissue after previous surgery or radiotherapy with higher sensitivity and equal 
specificity than MRI 23. This is of additional value to tailor the resection especially in 
recurrent, pretreated tumors. Thus, 68Ga-DOTATATE PET provides additional 
valuable information regarding extent and localization of meningioma tissue, 
especially when this information is being integrated into neuronavigation systems 62. 
 
 68Ga-DOTATATE PET improves the delineation of tumor extent in 
meningiomas with potential benefits for tumor resection (evidence level 2). 
 
 
Radiation Treatment Planning 
Target volume delineation plays a crucial role in the planning of high precision 
radiation therapy such as radiosurgery and stereotactic fractionated radiotherapy. In 
meningiomas, the GTV and the CTV is delineated based on image fusion of contrast-
enhanced CT and MRI. Usually, contrast-enhanced MRI visualizes very well the 
GTV. However, in a considerable number of cases, especially in tumors located at 
the skull base (meningiomas of the suprasellar region and the sphenoid wings 
comprise approximately 30% of cases), it is difficult to differentiate between normal 
dura tissue and tumor tissue, because normal dura as well as bone show a high 
contrast enhancement. Moreover, in tumors infiltrating the bone it is difficult to define 
the infiltration depth with high precision, despite using the bone window on CT 
images. In these cases, PET imaging may add helpful information. Furthermore, in 
postoperative MRI with inconclusive findings (e.g., reactive changes), PET may aid in 
the identification of active tumor remnants in the planning of adjuvant radiotherapy 
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after subtotal or partial tumor resection. For RT planning, it is necessary to fuse the 
PET with MRI/CT due to the lower spatial resolution of PET alone. 
 
11C-MET PET can be integrated in radiation treatment planning 63 and significantly 
influence GTV delineation in meningiomas. Astner and colleagues demonstrated that 
in 32 patients with benign skull base meningiomas treated with stereotactic 
fractionated radiotherapy the addition of 11C-MET PET changed the GTV in all but 
three patients 31. In that study, 11C-MET PET detected tumor areas with a mean 
volume of 1.6 ml, which were not visualized on CT or MRI, leading to an enlargement 
of GTV of approximately 9%. At the same time, areas without tumor infiltration could 
be excluded from the GTV and critical structures like optic nerves, the chiasm or the 
pituitary gland could be spared more effectively 31. Furthermore, regarding the GTV 
definition, the addition of 11C-MET PET to CT and MRI helps to significantly lower the 
interobserver variability in comparison to MRI and CT alone 59. Subsequently, other 
groups have confirmed these findings using other radiolabeled amino acids 58. 
 
Milker-Zabel et al. demonstrated an optimized target volume delineation for 
stereotactic fractionated radiation therapy in grade I-III meningiomas using 68Ga-
DOTATOC PET co-registered to CT and MRI 56. In all patients, 68Ga-DOTATOC PET 
delivered additional information concerning meningioma extent for fractionated 
stereotactic radiotherapy target definition. These results are supported by data 
reported subsequently by other groups 57,64,65 (Fig. 5, 6). 
 
 Amino acid PET and 68Ga-DOTATOC PET add valuable diagnostic 
information for meningioma delineation, particularly helpful for radiotherapy 
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planning by improving both GTV definition and dose sparing of organs at risk 
(evidence level 2).  
 
 
Follow-up: Treatment Response, Progression  
In a prospective study with 19 meningioma patients, serial 11C-MET PET scans were 
used to evaluate the effect of stereotactic high-energy proton beam treatment (24 Gy 
in four consecutive daily 6-Gy fractions) 66. The authors observed no significant 
reduction of tumor size but an average tumor/brain ratio reduction of 19% in the total 
patient group, suggesting that 11C-MET PET may enable an earlier evaluation of 
treatment effects than CT or MRI. The long-term evaluation over 10 years of the 
same patient cohort revealed that in the majority of patients MET uptake ratios 
showed a further decrease, whereas the tumor size was predominantly unchanged 
throughout the follow-up 67. As 68Ga-DOTATOC PET is superior in both 
discriminating meningioma tissue from scars related to pretreatment and detecting 
meningiomas not (yet) seen in MRI, it is useful in cases of unclear differential 
diagnosis between tumor progression and posttherapeutic reactive changes 23,24,52. 
For the discrimination of scar tissue from vital tumor, Rachinger and colleagues 
demonstrated that standard MRI has a lower diagnostic performance than 68Ga-
DOTATATE PET: sensitivity, 79% vs. 90%; specificity, 65% vs. 74%; and positive 
predictive value, 84% vs. 89% 23. In line with this, a more recent 68Ga-DOTATATE 
PET study with focus on transosseous growing meningiomas showed an even better 
diagnostic performance for pretreated lesions than standard MRI (sensitivity, 97% vs. 
54%; specificity, 100% vs. 83%; positive predictive value, 100% vs. 95%; and 
negative predictive value, 86% vs. 23%) 61.  
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 Up to now, only preliminary evidence for a potential benefit of amino acid PET 
for treatment monitoring of radiotherapy is present (evidence level 3). 
 
 68Ga-DOTATOC PET can be useful in cases of unclear differential diagnosis 
between tumor progression and posttherapeutic reactive changes (evidence 
level 2). 
 
 
CURRENT LIMITATIONS  
PET data in relation to the clinical management of meningioma patients have 
predominantly been reported for small, retrospectively assembled patient series, and 
data were usually obtained in monocentric studies. Recent encouraging findings in 
this field should therefore be validated in larger clinical prospective multicenter 
cohorts and trials. Moreover, further studies evaluating the correlation between PET 
imaging findings and histology are necessary and essential to define more accurately 
the impact of PET in this group of patients. Importantly, it has still to be demonstrated 
that a better tumor delineation allows better long term tumor control. Another 
methodical concern of using PET for planning radiotherapy of meningioma is the 
definition of threshold values defining the radiation volumes (e.g., GTV). Because 
meningiomas may have microscopic tumor growth and PET has a limited spatial 
resolution, empirical margins have to be added. 
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OUTLOOK PERSPECTIVE  
 
Radiopeptide therapy  
 
By exchanging the radionuclide, the same tracer can be use either for diagnostics or 
for therapy (“theranostics”). The principle of peptide receptor radionuclide therapy 
(PRRT) is well established in the management of neuroendocrine tumors 68, and 
more recently, has been introduced to meningioma treatment. An exchange of the 
short-lived positron emitter Gallium-68 used for PET with the longer-lived β-emitters 
Lutetium-177 or Yttrium-90 allows for receptor-targeted therapy. Due to the wide 
application in neuroendocrine tumors, the safety profile of SSTR-based PRRT is 
known and therapy is generally well tolerated.  
 
Eight studies and one single-case study on PRRT treatment in meningioma have 
been published, reporting on 90Y-DOTATOC, 177Lu-DOTATATE and 111In-
pentetreotide therapy in 124 patients 69-77. However, due to retro- and prospective 
study designs, mixed patient populations, differences in administered doses and 
varying response assessments as well as follow-up interval, pooling of the present 
data is complex. Nevertheless, the high rate of reported disease stabilization and the 
possibility of a patient- or lesion-tailored therapy make PRRT a promising tool; 
however, future studies should include an adequate sample size with clear inclusion 
criteria, preferably include a comparator to PRRT and rigorous response assessment 
to determine the role of PRRT in meningioma management. In the future perspective, 
PRRT may be further optimized by a change to α-emitters and local application of the 
substance to increase the locally administered dose 78,79. 
 
 
 
 
N-O-D-17-00255R2 
 
 20 
CONCLUSION 
Compared to standard MRI, particularly PET ligands to SSTR (receptor subtype 2) 
add valuable additional diagnostic information. Based on the current levels of 
evidence, the most relevant indications for this group of tracers are differential 
diagnosis of newly diagnosed brain lesions suspicious for meningiomas, the 
delineation of meningioma extent in regions with low MR and CT contrast (e.g., 
osseus infiltration) and complex anatomy (e.g., skull base) for resection or 
radiotherapy planning, and the differentiation of tumor progression from 
posttherapeutic reactive changes such as scar tissue or radiation necrosis. The 
evidence in this field justifies therefore a further validation in larger prospective 
multicenter clinical cohorts and trials for which standardized technical guidelines for 
imaging and readout procedures will now be developed. 
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FIGURE LEGENDS 
Figure 1: 43-year-old male patient with a newly diagnosed left temporal meningioma 
(WHO grade I), preoperatively examined by multimodal imaging. Both contrast-
enhanced MRI and 18F-FET PET allow a precise tumor delineation. Conversely, 18F-
FDG PET shows decreased metabolic activity, indicating its limitation for the 
evaluation of meningioma extent. 
  
Figure 2: Postoperative contrast-enhanced MRI and 68Ga-DOTATATE PET/CT of a 
32-year-old patient after resection of a WHO grade I meningioma shows residual 
tumor located at the left internal carotid artery and at tumor at the tip of the left orbit 
(A, D). Surprisingly, two additional meningiomas were also visible on the 68Ga-
DOTATATE PET/CT (E, F), without corresponding contrast enhancement on MRI (B, 
C).       
  
Figure 3: 43-year-old female patient with a history of a meningioma of the left optical 
sheath treated with surgery and radiotherapy eight years ago. At follow-up, 68Ga-
DOTATATE-PET/CT reveals multiple meningioma lesions including meningioma 
recurrence at the optical sheath (arrows). 
  
Figure 4: Amino acid PET with 18F-FET and contrast-enhanced MR images of a 68-
year-old female meningioma patient (WHO grade I) with suspected recurrence 9 
years after tumor resection at initial diagnosis. 18F-FET PET identifies three 
hypermetabolic lesions, consistent with meningioma recurrence. In contrast, MRI 
shows prominent contrast enhancement in only two of three lesions. In that lesion 
(arrow, bottom), contrast enhancement is subtle and not well defined. 18F-FET PET 
allows an improved delineation of this lesion (arrow, top). 
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Figure 5: 42-year-old patient with exophthalmus and a history of a left sphenoid wing 
meningioma. Preoperative MRI shows tumor recurrence (top). Postoperative MRI 
(bottom left) shows an incomplete resection of the tumor, necessitating adjuvant 
radiotherapy. For radiotherapy planning, 68Ga-DOTATATE PET/CT reveals an 
additional tumor located at the tip of the right sphenoid wing (arrow, bottom right). 
 
Figure 6: Patient with a WHO grade I meningioma (arrows). In contrast to structural 
MRI, particularly 68Ga-DOTATOC PET delineates meningioma extent more precisely. 
For radiotherapy planning, the contralateral unaffected side can be spared.
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Table 1: Overview on the most relevant indications for PET imaging in meningioma patients 
Clinical 
indication 
PET Ligands for 
Somatostatin Receptors 
Amino acid PET tracers Other PET tracers 
Detection of meningioma tissue / 
 
differential diagnosis 
68Ga-DOTATOC and 
68Ga-DOTATATE PET may add 
valuable diagnostic information 24,53 
n.a. n.a. 
Meningioma 
grading 
68Ga-DOTATATE binding correlates 
with tumor growth rate in WHO grade 
I and II meningiomas 35 
11C-MET correlates with proliferative 
acivity 54, but data on grading are 
controversial 34,55 
 
Static and dynamic 18F-FET PET may 
provide additional information for 
meningioma grading 32 
11C-Choline seems to be helpful for 
meningioma grading 41 
 
11C-Acetate seems not to be helpful 18 
Delineation of tumor extent for 
resection planning 
68Ga-DOTATATE PET delineates 
better the meningioma extent than 
standard MRI 23,61 
n.a. n.a. 
Delineation of tumor extent for 
radiation treatment planning 
68Ga-DOTATOC PET delivers 
additional information on tumor extent 
for radiotherapy target definition 
56,57,64,65 
11C-MET PET influences significantly 
GTV delineation in meningiomas 31,59 
n.a. 
Treatment 
monitoring 
n.a. 
11C-MET PET allows an earlier 
evaluation of treatment effects  
than standard imaging 66,67 
 
boronated amino acid PET probes 
may help to evaluate treatment 
effects38 
n.a. 
Diagnosis of 
tumor progression / 
 
Differentiation of tumor progression 
from posttreatment changes 
68Ga-DOTATOC / 68Ga-DOTATATE 
PET is useful for differerentiation 
between progression and 
posttreatment changes 23,24,52 
n.a. n.a. 
 
n.a. = not available; GTV = gross tumor volume 
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